3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 3
2
Phase 1
2
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
pembrolizumab
80
Carboplatin
73
Paclitaxel
58
Cisplatin
58
Specimen Handling
56
Magnetic Resonance Spectroscopy
56
Gemcitabine
48
Docetaxel
37
Dexamethasone
37
Oxaliplatin
34
Fluorouracil
33
Bevacizumab
33
Pemetrexed
32
Leucovorin
32
Doxorubicin
32
Cyclophosphamide
31
durvalumab
29
Radiotherapy
29
Radiation
28
Capecitabine
28
Rituximab
25
Letrozole
25
Etoposide
24
Nivolumab
23
Irinotecan
23
Vincristine
22
Taxes
21
Lenalidomide
21
Prednisone
20
Bortezomib
20
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
polatuzumab vedotin
×
30 days
×
Clear all
NCT03274492
2026-05-08
POLARIX
Hoffmann-La Roche
Phase 3
Completed
1,000 enrolled
1 FDA
NCT05171647
2026-05-07
SUNMO
Hoffmann-La Roche
Phase 3
Active not recruiting
208 enrolled
12 charts